From Casetext: Smarter Legal Research

Regeneron Pharm., Inc. v. Merus N.V.

Supreme Court of the United States
Oct 1, 2018
139 S. Ct. 122 (2018)
Download
PDF
Check
Treatment

Summary

affirming finding of inequitable conduct and rendering patents unenforceable for a patentee who made false "factual representations" about the state of the art

Summary of this case from PPS Data, LLC v. Jack Henry & Assocs., Inc.
See 1 Summary

Opinion

No. 17–1616.

10-01-2018

REGENERON PHARMACEUTICALS, INC., petitioner, v. MERUS N.V.

Motion of Seven Chicago Patent Lawyers for leave to file a brief as amici curiae granted. Petition for writ of certiorari to the United States Court of Appeals for the Federal Circuit denied.

Summaries of

Regeneron Pharm., Inc. v. Merus N.V.

Supreme Court of the United States
Oct 1, 2018
139 S. Ct. 122 (2018)

affirming finding of inequitable conduct and rendering patents unenforceable for a patentee who made false "factual representations" about the state of the art

Summary of this case from PPS Data, LLC v. Jack Henry & Assocs., Inc.
Case details for

Regeneron Pharm., Inc. v. Merus N.V.

Case Details

Full title:REGENERON PHARMACEUTICALS, INC., petitioner, v. MERUS N.V.

Court:Supreme Court of the United States

Date published: Oct 1, 2018

Citations

139 S. Ct. 122 (2018)
202 L. Ed. 2d 197

Citing Cases

PPS Data, LLC v. Jack Henry & Assocs., Inc.

A broad range of sanctions, ranging from a finding of inequitable conduct to assertions of malpractice, are a…

DynaEnergetics Eur. GmbH v. Hunting Titan, Inc.

Prior art is not but-for material if it is merely cumulative. Regeneron Pharmaceuticals, Inc. v. Merus N.V.,…

2 Citing Cases